- Home
- BDSX vs SFST Comparison
BDSX vs SFST Comparison
Compare BDSX & SFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDSX
- SFST
- Stock Information
- Founded
- BDSX 2005
- SFST 1999
- Country
- BDSX United States
- SFST United States
- Employees
- BDSX N/A
- SFST N/A
- Industry
- BDSX Precision Instruments
- SFST Major Banks
- Sector
- BDSX Health Care
- SFST Finance
- Exchange
- BDSX Nasdaq
- SFST Nasdaq
- Market Cap
- BDSX 257.0M
- SFST N/A
- IPO Year
- BDSX 2020
- SFST 1999
- Fundamental
- Price
- BDSX $1.69
- SFST $33.60
- Analyst Decision
- BDSX Strong Buy
- SFST Buy
- Analyst Count
- BDSX 4
- SFST 1
- Target Price
- BDSX $3.08
- SFST $44.00
- AVG Volume (30 Days)
- BDSX 238.2K
- SFST 21.2K
- Earning Date
- BDSX 11-05-2024
- SFST 10-17-2024
- Dividend Yield
- BDSX N/A
- SFST N/A
- EPS Growth
- BDSX N/A
- SFST N/A
- EPS
- BDSX N/A
- SFST 1.70
- Revenue
- BDSX $60,902,000.00
- SFST $88,995,000.00
- Revenue This Year
- BDSX $48.06
- SFST N/A
- Revenue Next Year
- BDSX $29.97
- SFST $13.55
- P/E Ratio
- BDSX N/A
- SFST $19.66
- Revenue Growth
- BDSX 46.25
- SFST N/A
- 52 Week Low
- BDSX $1.15
- SFST $24.98
- 52 Week High
- BDSX $2.21
- SFST $39.36
- Technical
- Relative Strength Index (RSI)
- BDSX 44.40
- SFST 56.42
- Support Level
- BDSX $1.66
- SFST $33.26
- Resistance Level
- BDSX $1.80
- SFST $34.53
- Average True Range (ATR)
- BDSX 0.08
- SFST 0.85
- MACD
- BDSX -0.01
- SFST -0.01
- Stochastic Oscillator
- BDSX 38.46
- SFST 45.28
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.